Literature DB >> 34432243

Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.

Sarah D Mahan1, Kristin M Riching1, Marjeta Urh1, Danette L Daniels2.   

Abstract

Heterobifunctional small-molecule degraders known as Proteolysis Targeting Chimeras (PROTACs) serve as a chemical bridge bringing into direct association a target protein with an active E3 ligase complex, called the ternary complex, to facilitate targeted protein degradation. This ternary complex formation is the first key mechanistic step in a cascade of events that results in ubiquitination and subsequent degradation of the target protein via the ubiquitin-proteasome pathway. The ternary complex, however, is a nonnative cellular complex; therefore, PROTAC compound design has many challenges to overcome to ensure successful formation, including achieving structural and electrostatic favorability among target and ligase. Due to these challenges, finding successful PROTACs typically requires testing of extensive libraries of heterobifunctional compounds with varying linkers and E3 handles. As PROTAC ternary complex formation is also critically dependent on cellular context, live cell assays and technologies for rapid and robust screening are highly enabling for triaging of early stage compounds. Here, we present cellular assays utilizing NanoBRET technology for the study of ternary complexes, showing examples with two most popular PROTAC E3 ligase components, VHL (von Hippel-Lindau disease tumor suppressor) and CRBN (Cereblon). These assays can be run in either endpoint or real-time kinetic formats, are compatible with high-throughput workflows, and provide insight into how altering the PROTAC chemical composition affects the formation and stability of the ternary complex in live cells.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CRBN; Cellular ternary complex; E3 ligase components; Kinetic; NanoBRET; PROTACs; Protein degradation; Ubiquitination; VHL

Mesh:

Substances:

Year:  2021        PMID: 34432243     DOI: 10.1007/978-1-0716-1665-9_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  37 in total

1.  Protein degradation: Prime time for PROTACs.

Authors:  Raymond J Deshaies
Journal:  Nat Chem Biol       Date:  2015-09       Impact factor: 15.040

2.  Protein degradation for drug discovery.

Authors:  Alessio Ciulli; William Farnaby
Journal:  Drug Discov Today Technol       Date:  2019-04

3.  Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.

Authors:  Daniel P Bondeson; Blake E Smith; George M Burslem; Alexandru D Buhimschi; John Hines; Saul Jaime-Figueroa; Jing Wang; Brian D Hamman; Alexey Ishchenko; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-11-09       Impact factor: 8.116

Review 4.  Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Authors:  Ian Churcher
Journal:  J Med Chem       Date:  2017-12-19       Impact factor: 7.446

5.  Inducing Protein Degradation as a Therapeutic Strategy.

Authors:  Craig M Crews
Journal:  J Med Chem       Date:  2017-11-22       Impact factor: 7.446

Review 6.  Development of targeted protein degradation therapeutics.

Authors:  Philip P Chamberlain; Lawrence G Hamann
Journal:  Nat Chem Biol       Date:  2019-09-16       Impact factor: 15.040

Review 7.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

8.  HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.

Authors:  Dennis L Buckley; Kanak Raina; Nicole Darricarrere; John Hines; Jeffrey L Gustafson; Ian E Smith; Afjal H Miah; John D Harling; Craig M Crews
Journal:  ACS Chem Biol       Date:  2015-06-23       Impact factor: 5.100

Review 9.  Targeted Protein Degradation: from Chemical Biology to Drug Discovery.

Authors:  Philipp M Cromm; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-06-22       Impact factor: 8.116

Review 10.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.

Authors:  George M Burslem; Craig M Crews
Journal:  Cell       Date:  2020-01-16       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.